StockData
Monopar Therapeutics logo

Monopar Therapeutics (MNPR) stock

MNPRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$70.29−0.46 (-0.65%)

Close on Nov 19, 2026Market cap $471.80MP/E –Yield –

Monopar Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Monopar Therapeutics's revenue for the twelve months ending Dec 31, 2019 was $0. For fiscal 2025 it was $0. The highest annual figure on record is $0 in fiscal 2016.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$0–
FY2024Dec 31, 2024$0–
FY2019Dec 31, 2019$0–
FY2018Dec 31, 2018$0–
FY2017Dec 31, 2017$0–
FY2016Dec 31, 2016$0–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$0–
Q1 FY2026Mar 31, 2026$0–
Q4 FY2019Dec 31, 2019$0–
Q3 FY2019Sep 30, 2019$0–
Q2 FY2019Jun 30, 2019$0–
Q1 FY2019Mar 31, 2019$0–
Q4 FY2018Dec 31, 2018$0–
Q3 FY2018Sep 30, 2018$0–
Q2 FY2018Jun 30, 2018$0–
Q1 FY2018Mar 31, 2018$0–
Q4 FY2017Dec 31, 2017$0–
Q3 FY2017Sep 30, 2017$0–
Q2 FY2017Jun 30, 2017$0–
Q1 FY2017Mar 31, 2017$0–

More Monopar Therapeutics figures

See a number that looks wrong?